ALKS – Alkermes plc
ALKS — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
12.08
Margin Of Safety %
-27
Put/Call OI Ratio
1.05
EPS Next Q Diff
0.64
EPS Last/This Y
-0.49
EPS This/Next Y
0.57
Price
38.3
Target Price
45.19
Analyst Recom
1.44
Performance Q
10.28
Upside
-17.7%
Beta
0.32
Ticker: ALKS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-13 | ALKS | 33.76 | 1.11 | 0.26 | 10419 |
| 2026-04-14 | ALKS | 33.88 | 1.09 | 0.75 | 10631 |
| 2026-04-15 | ALKS | 33.2 | 1.08 | 0.50 | 10675 |
| 2026-04-20 | ALKS | 34.22 | 1.54 | 0.08 | 6442 |
| 2026-04-23 | ALKS | 33.92 | 1.45 | 0.82 | 6712 |
| 2026-04-24 | ALKS | 33.3 | 1.44 | 0.20 | 6769 |
| 2026-04-27 | ALKS | 33.7 | 1.43 | 0.08 | 6806 |
| 2026-04-28 | ALKS | 34.1 | 1.20 | 0.13 | 7360 |
| 2026-04-29 | ALKS | 33.72 | 1.16 | 0.59 | 7543 |
| 2026-04-30 | ALKS | 33.7 | 1.15 | 1.80 | 7660 |
| 2026-05-01 | ALKS | 33.37 | 1.15 | 6.00 | 7708 |
| 2026-05-04 | ALKS | 34.14 | 1.17 | 1.41 | 7762 |
| 2026-05-05 | ALKS | 36.26 | 1.20 | 0.34 | 7765 |
| 2026-05-06 | ALKS | 35.31 | 1.06 | 0.09 | 8660 |
| 2026-05-07 | ALKS | 35.4 | 1.06 | 0.08 | 8708 |
| 2026-05-08 | ALKS | 35 | 1.04 | 0.20 | 8814 |
| 2026-05-11 | ALKS | 35.48 | 1.04 | 0.14 | 8822 |
| 2026-05-12 | ALKS | 38.3 | 1.05 | 0.37 | 8790 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-13 | ALKS | 33.74 | -26.9 | 160.5 | 2.35 |
| 2026-04-14 | ALKS | 33.88 | -26.9 | 162.6 | 2.35 |
| 2026-04-15 | ALKS | 33.21 | -26.9 | 152.3 | 2.35 |
| 2026-04-16 | ALKS | 33.76 | -26.9 | 160.8 | 2.35 |
| 2026-04-17 | ALKS | 34.51 | -26.9 | 172.2 | 2.35 |
| 2026-04-20 | ALKS | 34.21 | -26.9 | 167.6 | 2.35 |
| 2026-04-21 | ALKS | 33.51 | -113.7 | 156.9 | 0.06 |
| 2026-04-22 | ALKS | 33.75 | -113.7 | 160.6 | 0.06 |
| 2026-04-23 | ALKS | 33.91 | -113.7 | 163.1 | 0.06 |
| 2026-04-24 | ALKS | 33.30 | -113.7 | 153.8 | 0.06 |
| 2026-04-27 | ALKS | 33.73 | -113.7 | 160.3 | 0.06 |
| 2026-04-28 | ALKS | 34.15 | -113.7 | 166.6 | 0.06 |
| 2026-04-30 | ALKS | 33.72 | -113.7 | 160.2 | 0.06 |
| 2026-05-01 | ALKS | 33.38 | -113.7 | 154.9 | 0.06 |
| 2026-05-04 | ALKS | 34.15 | -113.7 | 166.7 | 0.06 |
| 2026-05-05 | ALKS | 36.26 | -113.7 | 198.6 | 0.06 |
| 2026-05-06 | ALKS | 35.30 | -113.7 | 153.3 | 0.06 |
| 2026-05-07 | ALKS | 35.40 | -92.6 | - | 0.06 |
| 2026-05-08 | ALKS | 35.00 | -92.6 | - | 0.06 |
| 2026-05-11 | ALKS | 35.48 | - | - | -0.56 |
| 2026-05-12 | ALKS | 38.30 | -72.7 | - | 0.98 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-13 | ALKS | -4.06 | 3.29 | 11.67 |
| 2026-04-14 | ALKS | -4.06 | 3.29 | 11.67 |
| 2026-04-15 | ALKS | -4.06 | 3.29 | 11.67 |
| 2026-04-16 | ALKS | -3.81 | 3.29 | 11.67 |
| 2026-04-17 | ALKS | -3.81 | 3.29 | 11.67 |
| 2026-04-20 | ALKS | -3.81 | 3.27 | 11.67 |
| 2026-04-21 | ALKS | -3.81 | 3.27 | 11.67 |
| 2026-04-22 | ALKS | -3.81 | 3.27 | 11.65 |
| 2026-04-23 | ALKS | -4.16 | 3.27 | 11.65 |
| 2026-04-24 | ALKS | -4.16 | 3.27 | 11.65 |
| 2026-04-27 | ALKS | -4.16 | 2.60 | 12.06 |
| 2026-04-28 | ALKS | -4.16 | 2.60 | 12.06 |
| 2026-04-29 | ALKS | -4.16 | 2.60 | 12.06 |
| 2026-04-30 | ALKS | -4.16 | 2.60 | 12.06 |
| 2026-05-01 | ALKS | -4.16 | 2.60 | 12.06 |
| 2026-05-04 | ALKS | -4.16 | 2.19 | 12.06 |
| 2026-05-05 | ALKS | -4.23 | 2.19 | 12.06 |
| 2026-05-06 | ALKS | -4.23 | 2.19 | 12.06 |
| 2026-05-07 | ALKS | -4.23 | 2.19 | 12.06 |
| 2026-05-08 | ALKS | -4.22 | 2.19 | 12.03 |
| 2026-05-11 | ALKS | -4.24 | 2.31 | 12.03 |
| 2026-05-12 | ALKS | -4.22 | 2.31 | 12.08 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.4
Avg. EPS Est. Current Quarter
0.19
Avg. EPS Est. Next Quarter
0.24
Insider Transactions
-4.22
Institutional Transactions
2.31
Beta
0.32
Average Sales Estimate Current Quarter
458
Average Sales Estimate Next Quarter
473
Fair Value
28.06
Quality Score
79
Growth Score
61
Sentiment Score
96
Actual DrawDown %
-4.6
Max Drawdown 5-Year %
-33.2
Target Price
45.19
P/E
42.57
Forward P/E
61.31
PEG
P/S
4.09
P/B
3.64
P/Free Cash Flow
28.77
EPS
0.9
Average EPS Est. Cur. Y
0.98
EPS Next Y. (Est.)
1.56
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
9.78
Relative Volume
1.69
Return on Equity vs Sector %
-18.1
Return on Equity vs Industry %
0.6
EPS 1 7Days Diff
0.9
EPS 1 30Days Diff
0.92
EBIT Estimation
◆
ALKS
Healthcare
$38.29
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
70.4
Range 1M
95.3%
Sup Dist
8.2%
Momentum Growth
Ride accelerating trends
WATCH
EPS Yr
-117%
EPS NY
356.5%
52W%
98%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+16.9% upside
Upside
+16.9%
Quality
79
MoS
-27%
Alkermes plcSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 2050
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
ALKS
Latest News
—
Caricamento notizie per ALKS…
stock quote shares ALKS – Alkermes plc Stock Price stock today
news today ALKS – Alkermes plc stock forecast ,stock prediction 2023 2024 2025
marketwatch ALKS – Alkermes plc yahoo finance google finance
stock history ALKS – Alkermes plc invest stock market
stock prices ALKS premarket after hours
ticker ALKS fair value insiders trading